Psychiatyr Clin Neurosci 58, 359-363, (2004). Satoh, F., Miyatake, R., Furukawa, A., & Suwaki, H View abstract in PubMed Post navigationPreviousPrevious post:Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumour and self-reliant cells and inhibit tumor growth in vitro and in vivo.NextNext post:Sigma-1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls.Related PostsAnavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect ConferenceJanuary 6, 2021Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
